Small-cap healthcare names produced the biggest share-price swings this week, while larger names advanced on sales growth, trial progress and fresh contracts. Investors rewarded companies that showed clear commercial traction, but fundraising and weak follow-through punished others.
- Memphasys led the board after outlining its shift to repeat cartridge revenue and wider offshore sales.
- Lumos fell hardest as a share purchase plan weighed on sentiment despite a new manufacturing contract.
- Telix, EBR and Pacific Edge gained on revenue growth, implants, reimbursement progress and regulatory steps.
Memphasys (ASX:MEM), Lumos Diagnostics (ASX:LDX) and Careteq (ASX:CTQ) set the pace for weekly moves. Memphasys surged 33.33% after telling investors its business is moving from early sales into broader commercial rollout, with repeat income from single-use cartridges. Lumos dropped 16.67% as the company launched a share purchase plan, which means existing holders were asked to put in more money at a set price. Careteq climbed 14.29% after completing a $5 million asset sale and paying back a related loan, giving the market a cleaner and simpler story.
Commercial progress drove buyers
EBR Systems (ASX:EBR) rose 13.56% after more than doubling WiSE implants in the March quarter and pointing to revenue of up to US$2.36 million. Investors cared because more implants mean the product is being used in real hospitals, not just talked about. Telix Pharmaceuticals (ASX:TLX) added 13.05% after posting US$230 million in quarterly revenue, keeping full-year guidance intact and reporting progress in prostate cancer therapy and imaging programs. Pacific Edge (ASX:PEB) gained 10.34% as test volumes rose and US insurance coverage improved. That matters because coverage by Medicare or private insurers can decide whether doctors order a test at scale.Cancer imaging and therapy stayed active
Radiopharmaceutical names remained busy. Telix added another catalyst when the US Food and Drug Administration accepted its application for TLX101-Px, a brain cancer imaging agent, and set a September review date. In plain terms, the regulator agreed to formally assess the product for approval. Radiopharm Theranostics (ASX:RAD) rose 4.76% after securing Siemens Healthineers as a supply partner for RAD101 and then reporting dose escalation progress for 177Lu-RAD202. Investors usually like this kind of update because it shows the company has both a trial plan and a manufacturing route.Regulatory wins helped, but the market still wanted proof of sales
Mesoblast (ASX:MSB) had two favourable updates. It won US clearance to start a key Duchenne muscular dystrophy study for Ryoncil, and it reported March-quarter Ryoncil sales of US$30.3 million. Even so, the stock slipped 0.47% for the week. That muted move suggests investors want to see sustained sales growth and smooth trial recruitment before paying more. Imricor Medical Systems (ASX:IMR) fell 2.14% despite seeking a paediatric label expansion for NorthStar. A label expansion means permission to sell for a broader patient group. The likely issue was timing: the filing is promising, but the extra hospital sales are still ahead, not here yet.Deals and contracts supported the larger names
Pro Medicus (ASX:PME) rose 6.80% after landing a five-year A$23 million deal with the University of Maryland Medical System for its cloud imaging platform. Early gains held and buying continued, which usually signals confidence that the contract is meaningful. Cogstate (ASX:CGS) climbed 7.98% after signing $25.4 million in new sales contracts and building its future revenue book. Little Green Pharma (ASX:LGP) was flat at 0.00% even after Cannatrek shareholders overwhelmingly approved the takeover scheme. The deal now moves to court approval on 24 April, so traders may be waiting for the last legal step.Capital raisings and leadership changes split opinion
Lumos showed the clearest example of early weakness getting worse. The stock reopened lower and then fell further, a sign that sellers were not done after the fundraising news. The company did announce a three-year manufacturing deal for its Mold Analyzer system, but that positive contract was not enough to offset dilution concerns. Dilution means existing holders may own a smaller share of the company after new shares are issued. ImpediMed (ASX:IPD) slipped 3.23% after naming a new chief executive focused on US growth. The shares reopened lower and kept drifting down, which suggests investors want evidence of higher sales before they back the leadership reset. By contrast, Neuren Pharmaceuticals (ASX:NEU) rose 4.07% as its partner widened US access to DAYBUE STIX for Rett syndrome, giving the market a clearer read on product uptake.Bottom Line?
The next fortnight brings several dates that could shape the group, including the Federal Court hearing on Little Green Pharma’s Cannatrek deal on 24 April, Lumos’ share purchase plan close on 24 April, and Telix’s September FDA review clock for TLX101-Px continuing to draw attention.
Questions in the middle?
- Can EBR turn its jump in implants into steady hospital ordering through the rest of 2026?
- Will Mesoblast’s Ryoncil sales keep building after the March-quarter rebound, or was that strength short-lived?
- Can Lumos offset fundraising pressure with enough commercial revenue from manufacturing and diagnostics contracts?